You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,303,155


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,303,155
Title: Treatment of conditions associated with impairment in the level of the parathyroid hormone
Abstract:A method for restoration of the circadian rhythm of parathyroid hormone (PTH) serum levels in a subject having osteoporosis, so as to restore a circadian rhythm of PTH levels which is similar to that existing in normal subjects is disclosed by administering a single daily dose of a composition consisting essentially of an effective amount of phosphate in the evening or at night, whereby the composition causes a circadian rhythm of PTH levels which peaks during the night, whereby the circadian rhythm of PTH levels is restored to that which is similar to that existing in normal subjects, thereby treating osteoporosis.
Inventor(s): Silver; Justin (Motza Illit, IL)
Assignee: Hadasit Medical Research Services and Development Company, Ltd. (Jerusalem, IL)
Application Number:09/258,907
Patent Claims:1. A method for restoration of the circadian rhythm of parathyroid hormone (PTH) serum levels in a subject having osteoporosis, so as to restore a circadian rhythm of PTH levels which is similar to that existing in normal subjects, comprising:

administering a single daily dose of a composition consisting essentially of an effective amount of phosphate in the evening or at night, prior to bedtime, whereby the composition causes a circadian rhythm of PTH levels which peaks during the night, whereby the circadian rhythm of PTH levels is restored to that which is similar to that existing in normal subjects, thereby treating the osteoporosis.

2. The method in accordance with claim 1, wherein said single daily dose is administered orally.

3. The method in accordance with claim 1, wherein said subject is a human subject.

4. The method in accordance with claim 1, further including the timed administration of an auxiliary agent capable of decreasing the PTH level, which administration is in the day time, whereby the result of the combined treatment is a rhythm of PTH which has a low level during the day time and a higher level during night time thereby giving rise to a circadian profile of PTH level similar to that existing in normal subjects.

5. The method in accordance with claim 4, wherein said auxiliary agent is calcium.

6. The method in accordance with claim 4, wherein said auxiliary agent is administered once in the early morning hours and once during mid-day.

7. The method in accordance with claim 1, wherein said phosphate is selected from the group consisting of sodium phosphate and potassium phosphate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.